C. Harvengt
- Pharmacology top 5%
- Antibiotics Pharmacokinetics and Efficacy 14
- Pharmacology and Obesity Treatment 9
- Pharmacogenetics and Drug Metabolism 8
-
- Diabetes, Cardiovascular Risks, and Lipoproteins 7
- Pharmacology top 5%
- Antibiotics Pharmacokinetics and Efficacy 14
- Pharmacology and Obesity Treatment 9
- Pharmacogenetics and Drug Metabolism 8
-
- Lipid metabolism and disorders 6
- Analytical Chemistry top 10%
- Analytical Methods in Pharmaceuticals 9
-
- Lipoproteins and Cardiovascular Health 12
-
- Cancer, Lipids, and Metabolism 7
- Co-authors
- J.P. DesagerF. HellerYves HorsmansJean‐Pierre DesagerR. HulhovenCatherine VandenplasP. De SchepperF. Lamy
- Journals
- American Journal of Clinical Nutrition (1 paper)The American Journal of Medicine (2 papers)Pharmacology & Therapeutics (1 paper)
- Partner nations
- BelgiumLuxembourgGermany
In The Last Decade
C. Harvengt
96 papers receiving 940 citations
Peers
Comparison fields: 5 of 102
- Pharmacology 155
- Endocrinology, Diabetes and Metabolism 280
- Pharmacology 193
- Cardiology and Cardiovascular Medicine 149
- Analytical Chemistry 63
Countries citing papers authored by C. Harvengt
This map shows the geographic impact of C. Harvengt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Harvengt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Harvengt more than expected).
Fields of papers citing papers by C. Harvengt
This network shows the impact of papers produced by C. Harvengt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Harvengt. The network helps show where C. Harvengt may publish in the future.
Co-authorship network
The 25 scholars most cited alongside C. Harvengt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1996 | 46 | |
| 2 | 1993 | 7 | |
| 3 | 1993 | 24 | |
| 4 | 1992 | 34 | |
| 5 | Les cholestases médicamenteuses secondaires à une atteinte canalaire. | 1991 | 2 |
| 6 | 1991 | 11 | |
| 7 | 1991 | 10 | |
| 8 | Sensibilité et spécificité du dosage des catécholamines urinaires et de leurs métabolites acides dans le diagnostic du neuroblastome chez l'enfant | 1990 | 4 |
| 9 | Plasma enoximone concentrations in cardiac patients | 1990 | 3 |
| 10 | 1987 | 8 | |
| 11 | Metabolic Interaction of Cimetidine With Alprazolam and Triazolam After Repeated Doses | 1984 | 1 |
| 12 | [Clinical-pharmacology of Lipid Lowering Drugs] | 1983 | 0 |
| 13 | Effects on plasma apoproteins AI and B induced by two estro-progestin preparations: monophasic versus triphasic. | 1983 | 5 |
| 14 | Disposition of Daunorubicin and Daunorubicin-dna Complex in Rabbits | 1983 | 1 |
| 15 | Hemodynamic-effects of Ar-l115 Bs in Severe Chronic Congestive Heart-failure | 1982 | 1 |
| 16 | 1982 | 22 | |
| 17 | Pharmacokinetics of Fenofibrate in Man | 1980 | 2 |
| 18 | In vitro binding of various biological substances by two hypocholesterolaemic resins. Cholestyramine and colestipol. | 1979 | 9 |
| 19 | Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers. | 1978 | 21 |
| 20 | Daunomycin and daunomycinol plasma levels measured by HPLC after perfusions of daunomycin and daunomycin-DNA complex in rabbits: a preliminary report. | 1977 | 3 |
About C. Harvengt
C. Harvengt is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Pharmacology, having authored 100 papers that have together received 1.0k indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (14 papers), Lipoproteins and Cardiovascular Health (12 papers), Pharmacology and Obesity Treatment (9 papers), Analytical Methods in Pharmaceuticals (9 papers), Pharmacogenetics and Drug Metabolism (8 papers), Cancer, Lipids, and Metabolism (7 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (7 papers) and Lipid metabolism and disorders (6 papers). The work is most often cited by research in Pharmacology (155 citations), Endocrinology, Diabetes and Metabolism (280 citations) and Pharmacology (193 citations). C. Harvengt has collaborated with scholars based in Belgium, Luxembourg and Germany. Frequent co-authors include J.P. Desager, F. Heller, Yves Horsmans, Jean‐Pierre Desager, R. Hulhoven, Catherine Vandenplas, P. De Schepper, Yves Horsmans, F. Lamy and Suzanne Pourbaix. Their work appears in journals such as American Journal of Clinical Nutrition, The American Journal of Medicine and Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.